Skip to main content
Equibles
OLMA logo

OLMA · Olema Pharmaceuticals, Inc.

Track OLMA — free

Use OLMA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about OLMA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$10.90 -0.41 (-3.63%) At close · Aug 20
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a development stage company, we expect to incur significant and increasing losses until regulatory approval is granted for palazestrant or OP-3136. Regulatory approval is not guaranteed and may never be obtained. As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term.”
View the 10-Q filed Aug 10, 2026
Market Cap
$989.60M
Shares
87.50M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.90 Open$11.10 Day$10.67–11.12 52W close$5.45–35.83 Avg vol 30d1.0M Short int16.0M · 18.2% float · 18.2d Short vol55% Last earningsMay 26, 2026 DataNov 2020–Aug 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Jun 4, 2027 Est · unconfirmed · in 41 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −38%
below
Price vs 50-day avg −3%
below
RSI (14) 46
neutral
MACD trend Negative
52-week position 18%
mid-range
Momentum
relative strength
Very Weak
1-month return −7%
trailing
6-month return −55%
trailing
YTD return −56%
this year
Relative strength −66%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $11 › 200d $18 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +24 funds added
Insider flow Distributing
Net -$291.2K over 90 days · 100% sells
Short interest Rising
18.24% of float · ▲ +5.7% MoM · 18.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
183 holders — mid 3-yr range
Squeeze score 77
high risk · 0–100
Fundamentals
Strong
EPS growth +15%
Y/Y
Free cash flow $-146.9M
Balance sheet $48.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 160%
annualized · 1-yr
Max drawdown −74%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−38% Bearish
Price vs 50-day avg
−3% Neutral
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
18% Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $11 › 200d $18 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +24 funds added
Insider flow Distributing
Net -$291.2K over 90 days · 100% sells
Short interest Rising
18.24% of float · ▲ +5.7% MoM · 18.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
183 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5 Now $11 · 18% Range high $36
vs 200-day avg -38% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
gross proceeds from follow-on public offering $218.5M the fourth quarter and full year 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OLMA
Olema Pharmaceuticals, Inc.
this stock
$989.60M -56.4% — — 18.2%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
183
% held
117.4%
Net QoQ
-2.1M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
222
View
Short & Settlement
Short Interest Rising
Shares short
16.0M
Days to cover
18.2d
Change
+861.4K sh
View
Short Volume
Short vol %
55%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
79
Value
$949
As of
Jul 28, 2026
View
Off-Exchange
Off-exchange %
35.2%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$291.2K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-162.5M
EPS diluted
$-1.87
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
17
View
Proposed Sales
Value
$146.4K
Shares
12.5K
Filed
Jul 24, 2026
View
Exempt Offerings
Offering
$250.0M
Filed
Dec 12, 2024
View
Earnings & Events
Earnings Calls
Last call
Jun 9, 2026
View
Investor Relations
Latest news
Olema Oncology Appoints Jason O’B…
Published
Aug 13, 2026
View

Performance

5D 20D 120D MTD YTD
OLMA +3.7% -7.2% -55.0% -4.8% -56.4%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY +5.7% -10.5% -66.1% -6.9% -68.2%
Key facts CIK 1750284 CUSIP 68062P106 13F (30d) 175 filings 172 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)